Allspring Global Investments Holdings LLC Has $880,000 Stake in 10x Genomics, Inc. (NASDAQ:TXG)

Allspring Global Investments Holdings LLC boosted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 2,280.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 38,963 shares of the company's stock after purchasing an additional 37,326 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in 10x Genomics were worth $880,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock valued at $35,000 after purchasing an additional 1,265 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in 10x Genomics by 74.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company's stock worth $37,000 after buying an additional 808 shares during the period. Covestor Ltd lifted its stake in 10x Genomics by 501.7% in the first quarter. Covestor Ltd now owns 1,047 shares of the company's stock valued at $39,000 after buying an additional 873 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock valued at $40,000 after buying an additional 1,025 shares during the period. Finally, Sound Income Strategies LLC acquired a new position in shares of 10x Genomics in the third quarter valued at approximately $46,000. Institutional investors own 84.68% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. cut their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research report on Wednesday. Jefferies Financial Group upgraded 10x Genomics from a "hold" rating to a "buy" rating and set a $24.00 price target on the stock in a report on Monday, July 22nd. Stephens reiterated an "overweight" rating and set a $30.00 price objective on shares of 10x Genomics in a report on Thursday, October 10th. The Goldman Sachs Group cut their target price on 10x Genomics from $16.00 to $14.00 and set a "sell" rating on the stock in a research note on Wednesday. Finally, UBS Group decreased their price target on shares of 10x Genomics from $25.00 to $20.00 and set a "neutral" rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, 10x Genomics currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.19.

10x Genomics Stock Performance

NASDAQ:TXG traded up $0.30 during mid-day trading on Friday, hitting $16.33. The stock had a trading volume of 1,899,014 shares, compared to its average volume of 1,705,114. 10x Genomics, Inc. has a twelve month low of $14.02 and a twelve month high of $57.90. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -10.67 and a beta of 1.85. The company's 50 day simple moving average is $19.85 and its 200 day simple moving average is $21.33.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.04. The company had revenue of $151.65 million during the quarter, compared to analysts' expectations of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The business's revenue was down 1.3% on a year-over-year basis. During the same period last year, the firm posted ($0.51) earnings per share. As a group, equities analysts forecast that 10x Genomics, Inc. will post -1.35 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Benjamin J. Hindson sold 4,351 shares of the company's stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $98,028.03. Following the transaction, the insider now owns 345,704 shares in the company, valued at approximately $7,788,711.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Benjamin J. Hindson sold 4,351 shares of the business's stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $98,028.03. Following the completion of the sale, the insider now directly owns 345,704 shares in the company, valued at $7,788,711.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Justin J. Mcanear sold 2,961 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $66,711.33. Following the transaction, the chief financial officer now owns 143,242 shares in the company, valued at $3,227,242.26. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,061 shares of company stock valued at $316,794 over the last ninety days. 10.03% of the stock is currently owned by company insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.